Galantamine

Generic Name
Galantamine
Brand Names
Razadyne
Drug Type
Small Molecule
Chemical Formula
C17H21NO3
CAS Number
357-70-0
Unique Ingredient Identifier
0D3Q044KCA
Background

Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantam...

Indication

Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.

Associated Conditions
Mild to Moderate Dementia Due to Alzheimer's Disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

Not Applicable
Completed
Conditions
Cocaine Abuse
Interventions
Drug: Galantamine
Drug: placebo
First Posted Date
2008-02-05
Last Posted Date
2021-03-15
Lead Sponsor
Yale University
Target Recruit Count
34
Registration Number
NCT00606801
Locations
🇺🇸

Veterans Affairs Hospital, West Haven, Connecticut, United States

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

First Posted Date
2007-12-04
Last Posted Date
2012-12-03
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
39
Registration Number
NCT00566735
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

First Posted Date
2007-07-31
Last Posted Date
2018-04-11
Lead Sponsor
Georgetown University
Target Recruit Count
43
Registration Number
NCT00509067
Locations
🇺🇸

Washington Veterans Affairs Medical Center, Washington, District of Columbia, United States

Galantamine for Cognitive Deficits in Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
First Posted Date
2007-04-20
Last Posted Date
2007-12-12
Lead Sponsor
Yale University
Target Recruit Count
21
Registration Number
NCT00463879
Locations
🇺🇸

Connecticut Mental Health Center, Yale School of Medicine, New Haven, Connecticut, United States

Galantamine Augmentation of Escitalopram for Treatment of Depression

Phase 4
Terminated
Conditions
Depression
First Posted Date
2007-01-18
Last Posted Date
2007-01-18
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
20
Registration Number
NCT00423969
Locations
🇺🇸

IU Adult Psychiatric Clinic, Indianapolis, Indiana, United States

Galantamine for Cognition in People With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
First Posted Date
2006-05-03
Last Posted Date
2009-05-19
Lead Sponsor
North Suffolk Mental Health Association
Target Recruit Count
20
Registration Number
NCT00320736
Locations
🇺🇸

Freedom Trail Clinic, Boston, Massachusetts, United States

A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

Phase 3
Completed
Conditions
Alzheimer's Disease
First Posted Date
2006-04-03
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
139
Registration Number
NCT00309725

Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

Phase 3
Completed
Conditions
Alzheimer Disease
First Posted Date
2006-03-20
Last Posted Date
2011-02-01
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
241
Registration Number
NCT00304629

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Phase 3
Completed
Conditions
Alzheimer Disease
First Posted Date
2006-03-13
Last Posted Date
2011-05-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
398
Registration Number
NCT00301574

Galantamine Versus Placebo in Childhood Autism

Phase 3
Completed
Conditions
Autism
Childhood Autism
First Posted Date
2005-11-11
Last Posted Date
2007-01-29
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
20
Registration Number
NCT00252603
Locations
🇺🇸

UMDNJ Robert Wood Johnson Medical School - Dept of Psychiatry, Piscataway, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy